A Controlled Trial of High-Dose Intravenous Immune Globulin Infusions as Treatment for Dermatomyositis

New England Journal of Medicine

Volumn 329, Issue 27, 1993, Pages 1993-2000

  Dalakas, Marinos C ^a   Illa, Isabel ^a   Dambrosia, James M ^a   Soueidan, Shawke A ^a   Stein, Daniel P ^a   Otero, Carlos ^a   Dinsmore, Steven T ^a   Mccrosky, Susan ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; PLACEBO; PREDNISONE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYOSITIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN TISSUE; IMMUNE MEDIATED INJURY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE BIOPSY; MUSCLE STRENGTH; NEUROMUSCULAR DISEASE; PHYSICAL DISABILITY; PRIORITY JOURNAL; RASH;

ADOLESCENT; ADULT; DERMATOMYOSITIS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; MALE; MIDDLE AGED; MUSCLES; PREDNISONE;

EID: 0027729939     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199312303292704     Document Type: Article

References (37)

1. Dalakas MC Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991; 325: 1487-1498
2. Dalakas MC, ed. Polymyositis and dermatomyositis. Boston: Butterworths, 1988.
3. Dalakas MC Inflammatory myopathies. Curr Opin Neurol Neurosurg 1990; 3: 689-696
4. Banker BQ, Engel AG. The polymyositis and dermatomyositis syndromes. In: Engel AG, Banker BQ, eds. Myology. New York: McGraw-Hill, 1986:1385-422.
5. Rowland LP, ed. Merritt's textbook of neurology. 8th ed. Philadelphia: Lea & Febiger, 1989:733-8.
6. Dalakas MC. Inflammatory myopathies. In: Rowland LP, DiMauro S, eds. Handbook of clinical neurology. Vol. 18. Myopathies. Amsterdam: Elsevier Science, 1992:369-90.
7. Engel AG, Arahata K Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986; 17: 704-721
8. Engel AG, Arahata K Monoclonal antibody analysis of mononuclear cells in myopathies. II. Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-215
9. Emslie-Smith AM, Arahata K, Engel AG Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20: 224-231
10. Whitaker JN, Engel WK Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N Engl J Med 1972; 286: 333-338
11. Kissel JT, Mendell JR, Rammohan KW Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314: 329-334
12. Emslie-Smith AM, Engel AG Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990; 27: 343-356
13. Dalakas MC Inflammatory and toxic myopathies. Curr Opin Neurol Neurosurg 1992; 5: 645-654
14. Dalakas MC Clinical, immunopathologic, and therapeutic considerations of inflammatory myopathies. Clin Neuropharmacol 1992; 15: 327-351
15. Rowland LP, Clark C, Olarte M Therapy for dermatomyositis and polymyositis. Adv Neurol 1977; 17: 63-97
16. van der Meche FGA, Schmitz PIM, Dutch Guillain-Barre Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 1992; 326: 1123-1129
17. Soueidan SA, Dalakas MC Treatment of autoimmune neuromuscular diseases with high-dose intravenous immune globulin. Pediatr Res 1993; 33: Suppl: S95-S100
18. Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA 1987; 258: 513-515
19. Lang BA, Laxer RM, Murphy G, Silverman ED, Roifman CM Treatment of dermatomyositis with intravenous gammaglobulin. Am J Med 1991; 91: 169-172
20. Cherin P, Herson S, Wechsler B, Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991; 91: 162-168
21. Soueidan SA, Dalakas MC Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993; 43: 876-879
22. Mahoney FI, Barthel DW Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 61-65
23. Daniels L, Worthingham C. Muscle testing: techniques of manual examination. 3rd ed. Philadelphia: W.B. Saunders, 1972:2-3.
24. Miller FW, Leitman SF, Cronin ME, Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med 1992; 326: 1380-1384
25. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990; 322: 1098-1105
26. Illa I, Leon-Monzon M, Dalakas MC Regenerating and denervated human muscle fibers and satellite cells express neural cell adhesion molecule recognized by monoclonal antibodies to natural killer cells. Ann Neurol 1992; 31: 46-52
27. Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, 1975.
28. Stein DP, Dalakas MC Intercellular adhesion molecule-1 expression is upregulated in patients with dermatomyositis. Ann Neurol 1993; 34: 268-268 abstract.
29. Stein DP, Jordan SC, Toyoda M, Gallera O, Dalakas MC Antiendothelial cell antibodies (AECA) in dermatomyositis (DM). Neurology 1993; 43: Suppl: 356-356
30. Engel AG, Biesecker G Complement activation in muscle fiber necrosis: demonstration of the membrane attack complex of complement in necrotic fibers. Ann Neurol 1982; 12: 289-296
31. Dwyer JM Manipulating the immune system with immune globulin. N Engl J Med 1992; 326: 107-116
32. Gelfand EW Intervention in autoimmune disorders: creation of a niche for intravenous gamma-globulin therapy. Clin Immunol Immunopathol 1989; 53: S1-S6 [Erratum, Clin Immunol Immunopathol 1990;55:492.]
33. Ballow M Mechanisms of action of intravenous immunoglobulin therapy and potential use in autoimmune connective tissue diseases. Cancer 1991; 68: Suppl: 1430-1436
34. 8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993; 341: 789-790
35. Dustin ML, Springer TA Role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu Rev Immunol 1991; 9: 27-66
36. 3NeF in intravenous immunoglobulin. Lancet 1992; 340: 63-64
37. Basta M, Kirshbom P, Frank MM, Fries LF Mechanism of therapeutic effect of high-dose intravenous immunoglobulin: attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest 1989; 84: 1974-1981